Welcome, Guest. Please login or register.
November 26, 2024, 05:10:36 pm

Login with username, password and session length


Members
Stats
  • Total Posts: 55133
  • Total Topics: 4851
  • Online Today: 264
  • Online Ever: 3061
  • (September 25, 2024, 11:40:40 pm)
Users Online
Users: 0
Guests: 140
Total: 140

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Early phase studies of anti-fibrosis pharmaceutical  (Read 8366 times)

0 Members and 1 Guest are viewing this topic.

Offline elias

  • Member
  • Posts: 285
Early phase studies of anti-fibrosis pharmaceutical
« on: November 19, 2016, 04:48:23 pm »
]]http://liverlearning.aasld.org/aasld/2015/thelivermeeting/110677/[[$item.link]]

Quote
At the lowest planned dose 6 out of 8 subjects had at least 1 stage reduction in Ishak score (mean reduction 1.25, range 0-4, N=8), and 1 subject showed reduction of METAVIR score from F-3 to F-0 right after 5 weeks dosing. Conclusion: ND-L02-s0201 was well tolerated in both studies with no dose limiting toxicities up to 0.8 mg/kg (single) and of 0.2 mg/kg/week (multiple doses). The PK results were consistent between healthy subjects and patients as well as for single and multiple doses with no drug accumulation. Histologic improvement was seen in the majority of patients at the lowest dose studied.

A few days ago, November 10, 2016 Bristol-Myers Squibb purchased rights to development of Denko's anti-fibrosis  investigational  drug:

https://hepatitiscnewdrugs.blogspot.com/2016/11/bristol-myers-squibb-signs-exclusive.html

Nitto Denko's studies are for advanced fibrosis due to either NASH or HCV
« Last Edit: November 19, 2016, 07:20:10 pm by elias »
Contracted HCV ~age 12
Diagnosed: September 2016 GT2b
F3 by Fibrosure: 0.66
Necroinflammat activity: A3 0.76
================
VL Sep. 12, 2016: 1.44 million/ Log: 6.157
AST:71/ ALT:114   Sept. 1, 2016 Before treatment
==================
4 week after beginning  Epclusa:
Viral Load: UNDETECTED
AST 17/ALT 11
===============
Began Epclusa:  October 22, 2016
End of Treatment [EOT]: January 13. 2017
====================
EOT+4 Weeks: UNDETECTED
====================
SVR 12 April14-HCV Not Detected

Offline Lynn K

  • Global Moderator
  • Member
  • Posts: 4,546
  • Get tested, get treated, get cured, fight Hep c!
Re: Early phase studies of anti-fibrosis pharmaceutical
« Reply #1 on: November 20, 2016, 08:46:39 pm »
Wow! Excellent news thanks!
Genotype 1a
1978 contracted, 1990 Dx
1995 Intron A failed
2001 Interferon Riba null response
2003 Pegintron Riba trial med null response
2008 F4 Cirrhosis Bx
2014 12 week Sov/Oly relapse
10/14 fibroscan 27 PLT 96
2014 24 weeks Harvoni 15 weeks Riba
5/4/15 EOT not detected, ALT 21, AST 20
4 week post not detected, ALT 26, AST 28
12 week post NOT DETECTED (07/27/15)
ALT 29, AST 27 PLT 92
24 week post NOT DETECTED! (10/19/15)
44 weeks (3/11/16)  fibroscan 33, PLT 111, HCV NOT DETECTED!
I AM FREE!

Offline elias

  • Member
  • Posts: 285
Re: Early phase studies of anti-fibrosis pharmaceutical
« Reply #2 on: November 20, 2016, 09:37:06 pm »
Hi Lynn:

Ive seen  reports about other treatment being studied as well. This was only one I had saved so far.

There will be many now who have cleared HCV. So increasing demand for improving fibrosis. Some developments along those lines for NASH might be applicable for those cured of HCV
Contracted HCV ~age 12
Diagnosed: September 2016 GT2b
F3 by Fibrosure: 0.66
Necroinflammat activity: A3 0.76
================
VL Sep. 12, 2016: 1.44 million/ Log: 6.157
AST:71/ ALT:114   Sept. 1, 2016 Before treatment
==================
4 week after beginning  Epclusa:
Viral Load: UNDETECTED
AST 17/ALT 11
===============
Began Epclusa:  October 22, 2016
End of Treatment [EOT]: January 13. 2017
====================
EOT+4 Weeks: UNDETECTED
====================
SVR 12 April14-HCV Not Detected

Offline Lynn K

  • Global Moderator
  • Member
  • Posts: 4,546
  • Get tested, get treated, get cured, fight Hep c!
Re: Early phase studies of anti-fibrosis pharmaceutical
« Reply #3 on: November 21, 2016, 01:01:09 am »
Even so with the present state of my liver I seem to be limping along ok with my lumpy bumpy rock hard liver so far so as long as I don't get HCC I think I am ok now but yeah getting rid of ascities and edema, killer leg cramps probably from the duretic I take, and having my platelet count rise to normal range would be awesome too.
Genotype 1a
1978 contracted, 1990 Dx
1995 Intron A failed
2001 Interferon Riba null response
2003 Pegintron Riba trial med null response
2008 F4 Cirrhosis Bx
2014 12 week Sov/Oly relapse
10/14 fibroscan 27 PLT 96
2014 24 weeks Harvoni 15 weeks Riba
5/4/15 EOT not detected, ALT 21, AST 20
4 week post not detected, ALT 26, AST 28
12 week post NOT DETECTED (07/27/15)
ALT 29, AST 27 PLT 92
24 week post NOT DETECTED! (10/19/15)
44 weeks (3/11/16)  fibroscan 33, PLT 111, HCV NOT DETECTED!
I AM FREE!

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.